Immunic announced that Tamar Howson resigned from the Board and Compensation Committee to retire, and CEO Erik Lundgren was appointed as a Class II director.
| IndividualTamar HowsonErik Lundgren | RoleMember, Board of Directors; Member, Compensation CommitteeChief Executive Officer; Appointed Class II Director of the Board | Type of ChangeResignedAppointed | Effective DateJune 29, 2026July 5, 2026 | ReasonTransition into retirement; resignation not due to disagreement with the CompanyAppointment following recommendation of Nominating and Corporate Governance Committee | Replacement InfoErik Lundgren appointed to Board following her resignationWill serve until 2028 annual meeting or until successor elected; no successor disclosed | Background DetailsNot disclosedServes as the Company's Chief Executive Officer; party to previously disclosed employment agreement | Board/Committee Role ChangesResigned from Compensation Committee and BoardNot appointed to any Board committee |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.